Heidelberg Pharma AG and Partner Huadong Receive all Approvals for the Announced Transaction from the Authorities and Plan Capital Measure

As of 27th February 2022, Heidelberg Pharma and Huadong Medicine Co., Ltd., Hangzhou, China, (Huadong) have entered into a strategic partnership with the signing of an exclusive licensing agreement as well as an investment agreement regarding an equity investment in Heidelberg Pharma. The investment by Huadong is planned in August 2022 totaling EUR 105 million, representing 35% of outstanding shares after the transaction, consisting of a rights issue and a share transfer.

Heidelberg Pharma to Present New Data on its Proprietary ATAC® Technology Platform at the AACR Annual Meeting 2022

Heidelberg Pharma AG announced today that it will present preclinical data on its proprietary Amanitin-based ATAC® technology at the American Association for Cancer Research (AACR) 2022 Annual Meeting. The meeting will take place in New Orleans, Louisiana, USA, from 8th – 13th April 2022.

Details of the poster presentation:
Amatoxin-based antibody-drug conjugates induce immunogenic cell death and improve the anti-tumor efficacy of immune checkpoint inhibitors in humanized mouse models

Heidelberg Pharma Receives Milestone Payment from Partner Magenta for Dosing the First Patient with MGTA-117

Heidelberg Pharma AG today announced that its cooperation partner Magenta Therapeutics, Cambridge, MA, USA, (Magenta; NASDAQ: MGTA) has dosed the first patient with the development candidate MGTA-117 in a Phase I/II study. The achievement of this milestone triggered a milestone payment to Heidelberg Pharma.

Heidelberg Pharma AG Secures Financing Commitment From its Main Shareholder dievini

Heidelberg Pharma AG today announced that it has secured a financing commitment in the amount of up to EUR 36 million from its main shareholder dievini Hopp BioTech holding GmbH & Co. KG, Walldorf, Germany, (dievini). This commitment replaces the not yet fully used financing commitment from March 2021.
The detailed form of the financing will be decided by the management and supervisory boards of Heidelberg Pharma as well as dievini at a later date.
The financing commitment will enable Heidelberg Pharma to advance its business activities, in particular to completely conduct the clinical Phase I/IIa with HDP-101 and to further develop the candidates HDP-102 und HDP-103, if and to the extent that this is not achieved through potential alternative capital measures. Based on the current planning, the Company’s cash reach is secured until mid-2023.

Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2021

• Paul-Ehrlich-Institut follows the FDA in giving clearance to begin a Phase I/IIa trial of HDP-101; first trial centers initiated in the USA
• Gross issue proceeds of over EUR 20 million generated from private placement in June
• Significant advances made in partner projects
• Guidance revised

Heidelberg Pharma AG today reported on the first nine months of fiscal year 2021 (1 December 2020 – 31 August 2021) and the Group’s financial figures.

Dr. Jan Schmidt-Brand, CEO and CFO of Heidelberg Pharma AG, commented: “We are delighted to have achieved important milestones in recent weeks and to have cleared several organizational hurdles for our initial clinical trial of HDP-101. The first two trial centers were initiated recently, and we are now eagerly awaiting the inclusion of the first patient.